Document Detail

Cell survival patterns in the pedunculopontine tegmental nucleus of methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys and 6OHDA-lesioned rats: evidence for differences to idiopathic Parkinson disease patients?
MedLine Citation:
PMID:  16237536     Owner:  NLM     Status:  MEDLINE    
We explore the patterns of cell loss in the pedunculopontine tegmental nucleus (PpT), a major locomotor and muscle tone suppression centre of the brainstem, in two animal models of Parkinson disease, namely MPTP (methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-treated monkeys and 6-hydroxydopamine(6OHDA)-lesioned rats. Although there have been many studies documenting the loss of dopaminergic cells from the substantia nigra in these animal models, there has been little, if any, documentation of a loss of cells in the PpT. Results were obtained from macaque monkeys (Macaca fascicularis) and Sprague-Dawley rats. For the monkey series, animals were injected intramuscularly with MPTP (0.2 mg/kg) for 8 days consecutively and then allowed to survive for 21 days thereafter. Each monkey underwent behavioural assessment for parkinsonian symptoms. For the rat series, 6OHDA was injected into the midbrain using stereotactic coordinates. Rats were then allowed to survive for either 7, 14, 28, or 84 days thereafter. Monkey and rat brains were aldehyde-fixed and processed for routine tyrosine hydroxylase (TH; to label nigral dopaminergic cells) and nitric oxide synthase (NOs; to label PpT cholinergic cells) immunocytochemistry. In monkeys, the morphology, distribution and number of NOs(+) cells in the controls and MPTP-treated cases were very similar. In fact, in terms of number, there was only a 1% difference in the mean cell number between the controls and MPTP-treated cases. A comparable pattern was evident in 6OHDA-lesioned rats; there was no substantial difference in morphology, distribution and number of NOs(+) cells on the 6OHDA-lesioned cases when compared to the controls at each of the survival periods post-surgery. In summary, we show no loss of the large cholinergic/NOs(+) cells in the PpT in two animal models of Parkinson disease. This is in contrast to the heavy loss of these cells reported by previous findings in idiopathic Parkinson disease in patients.
Claire E Heise; Zui Chih Teo; Bradley A Wallace; Keyoumars Ashkan; Alim-Louis Benabid; John Mitrofanis
Related Documents :
572616 - Studies on the mechanism of post-etorphine catalepsy. modyfying effect of amphetamine, ...
2417166 - The toxic actions of mptp and its metabolite mpp+ are not mimicked by analogues of mptp...
1922966 - Age-related changes in locomotor behavior induced by mptp in rats.
2480086 - Tyrosine content, influx and accumulation rate, and catecholamine biosynthesis measured...
12681436 - The contribution of alpha2-adrenoceptor and opioid receptor mechanisms to antinocicepti...
4051946 - Effect of adenosine and aicar on atp content and regional contractile function in reper...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2005-11-12
Journal Detail:
Title:  Anatomy and embryology     Volume:  210     ISSN:  0340-2061     ISO Abbreviation:  Anat. Embryol.     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-11-24     Completed Date:  2006-09-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7505194     Medline TA:  Anat Embryol (Berl)     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  287-302     Citation Subset:  IM    
Department of Anatomy & Histology, University of Sydney, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Behavior, Animal / drug effects
Cell Survival
Disease Models, Animal
Motor Activity / drug effects
Neurons / drug effects,  pathology
Nitric Oxide Synthase Type I / analysis,  metabolism
Parkinsonian Disorders / chemically induced,  pathology*
Pedunculopontine Tegmental Nucleus / pathology*
Rats, Sprague-Dawley
Tyrosine 3-Monooxygenase / analysis,  metabolism
Reg. No./Substance:
1199-18-4/Oxidopamine; 28289-54-5/1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; EC Oxide Synthase Type I; EC 3-Monooxygenase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Predicting radionuclide transfer to wild animals: an application of a proposed environmental impact ...
Next Document:  The role of timing, duration, and frequency of inundation in controlling leaf litter decomposition i...